Different levels of lymphocyte adenosine deaminase in active and inactive forms of chronic liver disease

Area of Science:

• Immunology
• Hepatology
• Biochemistry

Background:

• Chronic liver disease (CLD) encompasses various conditions affecting liver function.
• Adenosine deaminase (ADA) is an enzyme involved in purine metabolism and immune cell function.
• Altered ADA activity has been observed in various inflammatory and autoimmune conditions.

Purpose of the Study:

• To investigate Adenosine deaminase (ADA) activity in peripheral blood mononuclear cells (PBMC) of patients with chronic liver disease (CLD).
• To determine the relationship between ADA levels and disease activity or treatment status in CLD.
• To explore the potential of ADA as a biomarker in CLD.

Main Methods:

• Measurement of ADA activity in PBMC samples from patients with CLD and healthy controls.
• Categorization of CLD patients into untreated chronic active hepatitis (CAH), CAH in remission, and inactive cirrhosis (IC).
• Correlation analysis of ADA levels with biochemical parameters and T cell percentages.

Main Results:

• Mean ADA levels were significantly decreased in patients with untreated CAH compared to controls.
• ADA levels in patients with CAH in remission and inactive cirrhosis were comparable to control values.
• No significant correlation was found between ADA levels and biochemical markers or T cell counts.

Conclusions:

• Reduced ADA activity in PBMC is associated with active inflammation in chronic liver disease (CLD).
• Normalization of ADA levels in CLD patients may indicate biochemical or histological remission.
• ADA activity in PBMC could serve as a potential indicator of disease activity and treatment response in CLD.